Jang G, Park R, Esteva E, Hsu P, Feng J, Upadhaya S
J Exp Med. 2025; 222(6).
PMID: 40072317
PMC: 11899982.
DOI: 10.1084/jem.20240587.
Tan J, Wang C, Hu Z, Zhang X
Exploration (Beijing). 2025; 5(1):20230094.
PMID: 40040824
PMC: 11875451.
DOI: 10.1002/EXP.20230094.
Hrckulak D, Onhajzer J, Krausova M, Stastna M, Kriz V, Janeckova L
Transgenic Res. 2025; 34(1):9.
PMID: 39786607
PMC: 11717838.
DOI: 10.1007/s11248-024-00429-2.
Cox A, Der C
Genes Dev. 2024; 39(1-2):132-162.
PMID: 39638567
PMC: 11789494.
DOI: 10.1101/gad.352081.124.
Jones-Weinert C, Mainz L, Karlseder J
Nat Rev Mol Cell Biol. 2024; .
PMID: 39614014
DOI: 10.1038/s41580-024-00800-5.
Shc1 cooperates with Frs2 and Shp2 to recruit Grb2 in FGF-induced lens development.
Wang Q, Li H, Mao Y, Garg A, Park E, Wu Y
bioRxiv. 2024; .
PMID: 39484547
PMC: 11527007.
DOI: 10.1101/2024.10.20.619055.
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K, Posa M, Shenoy R, Roychoudhury S
Cells. 2024; 13(14.
PMID: 39056802
PMC: 11274496.
DOI: 10.3390/cells13141221.
Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8 T cell activation and limit responsiveness to immunotherapy in mice.
Assouline B, Kahn R, Hodali L, Condiotti R, Engel Y, Elyada E
Nat Commun. 2024; 15(1):6162.
PMID: 39039076
PMC: 11263607.
DOI: 10.1038/s41467-024-50441-7.
Large-Scale Genome-Wide Optimization and Prediction of the Cre Recombinase System for Precise Genome Manipulation in Mice.
Hosur V, Erhardt V, Hartig E, Lorenzo K, Megathlin H, Tarchini B
Res Sq. 2024; .
PMID: 39011108
PMC: 11247941.
DOI: 10.21203/rs.3.rs-4595968/v1.
Large-Scale Genome-Wide Optimization and Prediction of the Cre Recombinase System for Precise Genome Manipulation in Mice.
Erhardt V, Hartig E, Lorenzo K, Megathlin H, Tarchini B, Hosur V
bioRxiv. 2024; .
PMID: 38948742
PMC: 11212873.
DOI: 10.1101/2024.06.14.599022.
The correlation between KRAS and TP53 gene mutations and early growth of pulmonary nodules.
Zhao B, Li B, Guo H, Zhao Q, Zhang X, Zhao H
J Cardiothorac Surg. 2024; 19(1):376.
PMID: 38926874
PMC: 11200870.
DOI: 10.1186/s13019-024-02927-0.
Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells.
Hindul N, Abbott L, Adan S, Straatman K, Fry A, Hirota K
J Biol Chem. 2024; 300(6):107409.
PMID: 38796063
PMC: 11234024.
DOI: 10.1016/j.jbc.2024.107409.
Deconstructing cancer with precision genome editing.
Johnson G, Gould S, Sanchez-Rivera F
Biochem Soc Trans. 2024; 52(2):803-819.
PMID: 38629716
PMC: 11088927.
DOI: 10.1042/BST20230984.
Monoallelic KRAS (G13C) mutation triggers dysregulated expansion in induced pluripotent stem cell-derived hematopoietic progenitor cells.
Lin H, Takagi M, Kubara K, Yamazaki K, Michikawa F, Okumura T
Stem Cell Res Ther. 2024; 15(1):106.
PMID: 38627844
PMC: 11021011.
DOI: 10.1186/s13287-024-03723-2.
The CLCF1-CNTFR axis drives an immunosuppressive tumor microenvironment and blockade enhances the effects of established cancer therapies.
Sweet-Cordero E, Marini K, Champion E, Lee A, Young I, Leung S
Res Sq. 2024; .
PMID: 38562778
PMC: 10984090.
DOI: 10.21203/rs.3.rs-4046823/v1.
A reversible epigenetic memory of inflammatory injury controls lineage plasticity and tumor initiation in the mouse pancreas.
Falvo D, Grimont A, Zumbo P, Fall W, Yang J, Osterhoudt A
Dev Cell. 2023; 58(24):2959-2973.e7.
PMID: 38056453
PMC: 10843773.
DOI: 10.1016/j.devcel.2023.11.008.
Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
Mariuzza R, Wu D, Pierce B
Front Immunol. 2023; 14:1303304.
PMID: 38045695
PMC: 10693334.
DOI: 10.3389/fimmu.2023.1303304.
A guide to ERK dynamics, part 2: downstream decoding.
Ram A, Murphy D, DeCuzzi N, Patankar M, Hu J, Pargett M
Biochem J. 2023; 480(23):1909-1928.
PMID: 38038975
PMC: 10754290.
DOI: 10.1042/BCJ20230277.
Structural insights into the complex of oncogenic KRas4B and Rgl2, a RalA/B activator.
Tariq M, Ikeya T, Togashi N, Fairall L, Kamei S, Mayooramurugan S
Life Sci Alliance. 2023; 7(1).
PMID: 37833074
PMC: 10576006.
DOI: 10.26508/lsa.202302080.
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I, Roman M, Welch C, Entrialgo-Cadierno R, Salmon M, Santos A
Nat Commun. 2023; 14(1):6332.
PMID: 37816716
PMC: 10564741.
DOI: 10.1038/s41467-023-41828-z.